Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1964 1
1975 1
1978 1
1980 1
1981 3
1982 2
1987 1
1989 1
2001 1
2003 5
2004 2
2005 4
2006 6
2008 1
2009 3
2010 4
2011 2
2012 2
2014 3
2015 4
2016 5
2017 7
2018 6
2019 15
2020 21
2021 22
2022 21
2023 37
2024 34

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

190 results

Results by year

Filters applied: . Clear all
Page 1
Safety and efficacy of zilucoplan in patients with generalised myasthenia gravis (RAISE): a randomised, double-blind, placebo-controlled, phase 3 study.
Howard JF Jr, Bresch S, Genge A, Hewamadduma C, Hinton J, Hussain Y, Juntas-Morales R, Kaminski HJ, Maniaol A, Mantegazza R, Masuda M, Sivakumar K, Śmiłowski M, Utsugisawa K, Vu T, Weiss MD, Zajda M, Boroojerdi B, Brock M, de la Borderie G, Duda PW, Lowcock R, Vanderkelen M, Leite MI; RAISE Study Team. Howard JF Jr, et al. Lancet Neurol. 2023 May;22(5):395-406. doi: 10.1016/S1474-4422(23)00080-7. Lancet Neurol. 2023. PMID: 37059508 Clinical Trial.
Deschloroclozapine, a potent and selective chemogenetic actuator enables rapid neuronal and behavioral modulations in mice and monkeys.
Nagai Y, Miyakawa N, Takuwa H, Hori Y, Oyama K, Ji B, Takahashi M, Huang XP, Slocum ST, DiBerto JF, Xiong Y, Urushihata T, Hirabayashi T, Fujimoto A, Mimura K, English JG, Liu J, Inoue KI, Kumata K, Seki C, Ono M, Shimojo M, Zhang MR, Tomita Y, Nakahara J, Suhara T, Takada M, Higuchi M, Jin J, Roth BL, Minamimoto T. Nagai Y, et al. Among authors: nakahara j. Nat Neurosci. 2020 Sep;23(9):1157-1167. doi: 10.1038/s41593-020-0661-3. Epub 2020 Jul 6. Nat Neurosci. 2020. PMID: 32632286
Secondary Progressive Multiple Sclerosis: A Review of Clinical Characteristics, Definition, Prognostic Tools, and Disease-Modifying Therapies.
Ziemssen T, Bhan V, Chataway J, Chitnis T, Campbell Cree BA, Havrdova EK, Kappos L, Labauge P, Miller A, Nakahara J, Oreja-Guevara C, Palace J, Singer B, Trojano M, Patil A, Rauser B, Hach T. Ziemssen T, et al. Among authors: nakahara j. Neurol Neuroimmunol Neuroinflamm. 2022 Nov 22;10(1):e200064. doi: 10.1212/NXI.0000000000200064. Print 2023 Jan. Neurol Neuroimmunol Neuroinflamm. 2022. PMID: 36414428 Free PMC article. Review.
Phase 1/2a clinical trial in ALS with ropinirole, a drug candidate identified by iPSC drug discovery.
Morimoto S, Takahashi S, Ito D, Daté Y, Okada K, Kato C, Nakamura S, Ozawa F, Chyi CM, Nishiyama A, Suzuki N, Fujimori K, Kondo T, Takao M, Hirai M, Kabe Y, Suematsu M, Jinzaki M, Aoki M, Fujiki Y, Sato Y, Suzuki N, Nakahara J; Pooled Resource Open-Access ALS Clinical Trials Consortium; Okano H. Morimoto S, et al. Among authors: nakahara j. Cell Stem Cell. 2023 Jun 1;30(6):766-780.e9. doi: 10.1016/j.stem.2023.04.017. Cell Stem Cell. 2023. PMID: 37267913 Free article. Clinical Trial.
A review of Bruton's tyrosine kinase inhibitors in multiple sclerosis.
Airas L, Bermel RA, Chitnis T, Hartung HP, Nakahara J, Stuve O, Williams MJ, Kieseier BC, Wiendl H. Airas L, et al. Among authors: nakahara j. Ther Adv Neurol Disord. 2024 Apr 17;17:17562864241233041. doi: 10.1177/17562864241233041. eCollection 2024. Ther Adv Neurol Disord. 2024. PMID: 38638671 Free PMC article. Review.
Safety and efficacy of eculizumab in Guillain-Barré syndrome: a multicentre, double-blind, randomised phase 2 trial.
Misawa S, Kuwabara S, Sato Y, Yamaguchi N, Nagashima K, Katayama K, Sekiguchi Y, Iwai Y, Amino H, Suichi T, Yokota T, Nishida Y, Kanouchi T, Kohara N, Kawamoto M, Ishii J, Kuwahara M, Suzuki H, Hirata K, Kokubun N, Masuda R, Kaneko J, Yabe I, Sasaki H, Kaida KI, Takazaki H, Suzuki N, Suzuki S, Nodera H, Matsui N, Tsuji S, Koike H, Yamasaki R, Kusunoki S; Japanese Eculizumab Trial for GBS (JET-GBS) Study Group. Misawa S, et al. Lancet Neurol. 2018 Jun;17(6):519-529. doi: 10.1016/S1474-4422(18)30114-5. Epub 2018 Apr 21. Lancet Neurol. 2018. PMID: 29685815 Clinical Trial.
Dysautonomia associated with immune checkpoint inhibitors.
Tezuka T, Okuzumi S, Nakashima C, Ide T, Imai S, Mitsuboshi S, Kuwahara Y, Takizawa T, Seki M, Minematsu N, Aragane N, Nakahara J, Hori S, Nakane S, Suzuki S. Tezuka T, et al. Among authors: nakahara j. J Neurol. 2023 Jul;270(7):3413-3423. doi: 10.1007/s00415-023-11667-5. Epub 2023 Mar 20. J Neurol. 2023. PMID: 36939931 Review.
Long-term safety and effectiveness of eculizumab in patients with aquaporin-4 antibody-positive neuromyelitis optica spectrum disorder: a 2-year interim analysis of post-marketing surveillance in Japan.
Nakashima I, Nakahara J, Yokote H, Manabe Y, Okamura K, Hasegawa K, Fujihara K. Nakashima I, et al. Among authors: nakahara j. Ther Adv Neurol Disord. 2023 Jun 30;16:17562864231181177. doi: 10.1177/17562864231181177. eCollection 2023. Ther Adv Neurol Disord. 2023. PMID: 37441104 Free PMC article.
190 results